Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A tough-to-treat melanoma combo delivers quality time. New long-term data from the IGNYTE trial show that RP1 (vusolimogene oderparepvec) plus nivolumab not only extended survival in patients with advanced melanoma who had already failed anti–PD-1 therapy, but that most of that survival time was spent in good health. The combo earned FDA accelerated approval in August 2026.
For patients with advanced melanoma who've already failed immunotherapy, the combination of RP1 (vusolimogene oderparepvec-wtpg) and nivolumab is proving to be more than just a survival boost — it's keeping patients feeling well while they live longer. Long-term data from the phase 1/2 IGNYTE trial, presented at the 2026 SITC Annual Meeting, show that 92% of overall survival time was spent with preserved health-related quality of life (HRQOL).
Among the 121 HRQOL-evaluable patients, the median overall survival reached 32.2 months, and the median quality-adjusted overall survival (QA-OS) was 26.4 months. Responders fared dramatically better than non-responders, accruing nearly 2.4x more quality-adjusted life-years. These findings supported the FDA's accelerated approval of the combination in August 2026.
By the Numbers:
Why it matters: Quality of life is often the missing piece in oncology data. These findings confirm that RP1 + nivolumab doesn't just extend survival — it does so without significantly compromising patients' wellbeing, a critical factor for both patients and clinicians weighing treatment options in this hard-to-treat population.
